PML4

Half-year 2022 results - The combination of the war in Ukraine, Natural Catastrophe events and the severe drought in Brazil affect SCOR’s profitability in H1 2022

Retrieved on: 
Thursday, July 28, 2022

The combination of the war in Ukraine, Natural Catastrophe events and the severe drought in Brazil affect SCORs profitability in H1 2022.

Key Points: 
  • The combination of the war in Ukraine, Natural Catastrophe events and the severe drought in Brazil affect SCORs profitability in H1 2022.
  • The combination of these events has significantly affected SCORs results, leading to a net loss of
    EUR -239 million for the first half of 2022, of which EUR -159 million was incurred in the second quarter.
  • The reduced profitability notably reflects the cost of the claims related to the drought that impacted corn and soy crops in southern regions of Brazil.
  • SCOR is currently adopting a more selective approach in Reinsurance P&C Lines, however the H1 2022 GWP growth is still benefitting from recent underwriting years.

New Data at ECTRIMS 2021 Highlight Biogen’s Focus on Patient-Centered Outcomes and Improving the MS Patient Experience

Retrieved on: 
Wednesday, October 13, 2021

Our focus on improving the MS patient experience continues to shape research initiatives across Biogens MS portfolio, as demonstrated by presentations at this years ECTRIMS meeting, said Maha Radhakrishnan, M.D., Chief Medical Officer at Biogen.

Key Points: 
  • Our focus on improving the MS patient experience continues to shape research initiatives across Biogens MS portfolio, as demonstrated by presentations at this years ECTRIMS meeting, said Maha Radhakrishnan, M.D., Chief Medical Officer at Biogen.
  • The proportion of patients with No Evidence of Disease Activity (NEDA) was 70.0 percent for Q6W and 67.4 percent for Q4W.
  • No Difference in Radiologic Outcomes for Natalizumab Patients on Extended Interval Dosing Compared with Standard Interval Dosing in MS PATHS.
  • Combined post-marketing data based on prescriptions and clinical trials exposure to TECFIDERA as of June 30, 2021.